

CLAIMS

- Sub
Q1
1. In a particulate drug delivery composition for intranasal delivery comprising a plurality of bioadhesive microspheres and a systemically active drug, the improvement comprising that at least 90 wt % of the microspheres of the composition have a diameter of between 0.1 μ m and 10 μ m.
2. A drug delivery composition according to Claim 1 wherein the microspheres are prepared from a material that will gel in contact with the mucosal surface.
- A Sub
Q2
3. A drug delivery composition according to Claim 1 ~~or 2~~ wherein the microspheres comprise starch, starch derivatives, gelatin, albumin, collagen, dextran or dextran derivatives.
4. A drug delivery composition according to Claim 3 wherein the microspheres are starch microspheres.
5. A drug delivery composition according to Claim 1 wherein the microsphere material is cross-linked.
- Sub
Q3
6. A drug delivery composition according to Claim 1 wherein the microspheres have been stabilised by heat treatment.
7. A drug delivery composition according to Claim 1 additionally comprising an absorption enhancer.
8. A drug delivery composition according to Claim 7 wherein the absorption enhancer is a surfactant, ~~a lysophosphatidyletholine or a~~ lysophosphatidylglycerol.

9. A drug delivery composition according to Claim 1 wherein the drug is a biologically active peptide.

5 10. A drug delivery composition according to Claim 9 wherein the peptide is insulin or calcitonin.

10 11. A system for intranasal drug delivery comprising a drug delivery composition according to Claim 1 and a container having an orifice through which the composition can be delivered to the nasal mucosa in a gas stream.

12. A system according to Claim 11 wherein the system is such that, in use, the product of the flow rate and the square of the microsphere aerodynamic diameter is greater than $2000 \mu\text{m}^2 \cdot \text{litres/min}$.

15 13. A method of delivering a drug to the nasal mucosa, comprising introducing a gas stream containing a composition according Claim 1 into the nose.

20 14. A method of treating diabetes comprising introducing a gas stream containing a composition according to Claim 1 wherein the systemically active drug is insulin into the nose.

*add
224*

*Pub
g1*